#329 Coughing up the evidence: Bronchodilators or inhaled steroids for post-infectious cough
CLINICAL QUESTION
Do bronchodilators or inhaled corticosteroids (ICS) improve post-infectious cough in adults without asthma?
BOTTOM LINE
Data is very limited with only two ICS randomized controlled trials (RCTs) (163 patients) and one bronchodilator RCT (92 patients). For adults, post-infectious cough scores may improve ~50% on placebo and ~5-10% more with ICS over 2 weeks. Ipratropium/salbutamol may resolve cough in more patients than placebo at day 10 (63% versus 31%) but most patients (>80%, regardless of treatment) will have cough resolution by day 20.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Differences statistically significant unless noted.
- ICS versus placebo:
- Four systematic reviews of treatments for persistent cough (4-9 RCTs, 335-750 patients): Interpretation limited by inclusion of RCTs with acute (<3 weeks)1,2 and chronic (>8 weeks)2,3 cough, and multiple drug classes.4
- Most useful systematic review2 (2 RCTs, 163 patients), mostly subacute cough (3-8 weeks):
- ICS 0.42 (standard mean difference) better than placebo. In clinical terms, placebo improved cough scores at ~2 weeks by ~50-56% and ICS improves ~2-13% more.
- Largest RCT5 (133 patients) also reported:
- Additional outcomes (days off work, nocturnal awakenings, adverse effects): No difference.
- Proportion of non-smokers with >50% cough improvement: 81% versus 54% (placebo), number needed to treat (NNT)=4.
- No improvement among smokers.
- Limitations: Not all patients had post-infectious cough; study industry funded.
- Most useful systematic review2 (2 RCTs, 163 patients), mostly subacute cough (3-8 weeks):
- Four systematic reviews of treatments for persistent cough (4-9 RCTs, 335-750 patients): Interpretation limited by inclusion of RCTs with acute (<3 weeks)1,2 and chronic (>8 weeks)2,3 cough, and multiple drug classes.4
- Bronchodilators versus placebo:
- One RCT6 of 92 patients (cough duration 3-4 weeks): Combination of nebulized salbutamol/ipratropium versus placebo.
- Proportion with ongoing cough at day 10: 37% versus 69% placebo, NNT=3.
- No difference at day 20 (both >80% resolved).
- Limitations: Small studies; non-validated cough scores; multiple outcomes.
- One RCT6 of 92 patients (cough duration 3-4 weeks): Combination of nebulized salbutamol/ipratropium versus placebo.
CONTEXT
- Post-infectious cough is a cough persisting 3-8 weeks after an acute respiratory illness.7
- One RCT8 compared beclomethasone and placebo in 72 patients with prolonged acute cough (10 days-3 weeks), so likely not true post-infectious (subacute) cough.
- ICS improved 3 of 6 outcomes over placebo on device-measured cough, but no difference in patient-reported symptoms.
- Guidelines suggest considering a trial of inhaled ipratropium or, if refractory, inhaled corticosteroids.9
- RCTs above did not include patients with COVID-19.
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
A very practical solution for controlling cough 69% is significant if one needs to be able to control cough in public
Excellent
thanks
Symbicort has definitely helped post Covid cough
Interesting!
it is common, and getting more so, for patients to ask for something so good to have evidence. I wonder if there are any “harms” as patients despite evidence are grateful for “something”
Helpful
easy read with useful information
Thank you
I have tried this on several occasions and it has seemed to work for my patients with subacute cough syndromes following a persisting cough
Aligns with my current practice